Computers & Electronics

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: A systematic review and economic evaluation

Description
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: A systematic review and economic evaluation
Published
of 200
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
Share
Transcript
  Health Technology Assessment 2010; Vol. 15: No. 10 Health Technology AssessmentNIHR HTA programmewww.hta.ac.uk February 2011 10.3310/hta15100 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation M Rodgers, D Epstein, L Bojke, H Yang, D Craig, T Fonseca, L Myers, I Bruce, R Chalmers, S Bujkiewicz, M Lai, N Cooper, K Abrams, D Spiegelhalter,    A Sutton, M Sculpher and N Woolacott  Appendices Go to main text  How to obtain copies of this and other HTA programme reports  An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and  private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.How to order:– fax (with credit card details  ) – post (with credit card details or  cheque  ) – phone during office hours (  credit card  only). Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows: Synergie UK (HTA Department)Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QWEmail: orders@hta.ac.ukTel: 0845 812 4000 – ask for ‘HTA Payment Services’ (out-of-hours answer-phone service)Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header Payment methods Paying by cheque  If you pay by cheque, the cheque must be in pounds sterling , made payable to University of Southampton  and drawn on a bank with a UK address. Paying by credit card You can order using your credit card by phone, fax or post. Subscriptions NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of  HTA on DVD ? Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD  is currently free of charge worldwide. The website also provides information about the HTA programme and lists the membership of the various committees. HTA  © Queen’s Printer and Controller of HMSO 2011. All rights reserved. 135Health Technology Assessment 2011; Vol. 15: No. 10DOI: 10.3310/hta15100  Appendix 1 Literature search strategies F ull details of all databases searched and search strategies are provided below. Numbers in brackets reflect the number of hits retrieved.󰀀e search strategy was designed for searching MEDLINE through the OvidSP interface and was adapted as appropriate for all other databases searched, taking into account differences in indexing terms and search syntax for each database. Clinical effectiveness: search for RCTS  MEDLINE: OvidSP    ■ http://ovidsp.ovid.com/󰀀e MEDLINE search covered the date range 1950 to week 5 May 2009 for adalimumab and 1 April 2004 to week 5 May 2009, using the search field ‘ed: Entry Date’, for etanercept and infliximab. 󰀀e search was carried out on 9 June 2009 and identified 399 records.󰀀e strategy uses the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, sensitivity-maximising version (lines 1–11). 202 1. randomized controlled trial.pt. (272,711)2. controlled clinical trial.pt. (79,394)3. randomized.ab. (182,345)4. placebo.ab. (112,659)5. drug therapy.fs. (1,317,603)6. randomly.ab. (132,262)7. trial.ab. (189,408)8. groups.ab. (909,284)9. or/1-8 (2,406,033)10. (animals not (humans and animals)).sh. (3,290,537)11. 9 not 10 (2,040,011)12. Arthritis, Psoriatic/ (2223)13. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (3596)14. 12 or 13 (4138)15. (etanercept or enbrel).ti,ab,rn. (2085)16. (infliximab or remicade).ti,ab,rn. (4715)17. 15 or 16 (5890)18. 11 and 14 and 17 (450)19. (200404$or 200405$or 200406$or 200407$or 200408$or 200409$ or 200410$or 200411$or 200412$or 2005$or 2006$or 2007$or 2008$ or 2009$).ed. (3,555,234)20. 18 and 19 (356)21. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab,rn. (1161)22. 11 and 14 and 21 (143)23. 20 or 22 (399)  136Appendix 1  MEDLINE In-Process & Other Non-Indexed Citations: OvidSP    ■ http://ovidsp.ovid.com/󰀀e MEDLINE In-Process & Other Non-Indexed Citations search, database dated 8 June 2009, was carried out on 9 June 2009 and identified five records.󰀀e strategy sess the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, sensitivity-maximising version (lines 1–11).1. randomized controlled trial.pt. (387)2. controlled clinical trial.pt. (40)3. randomized.ab. (7406)4. placebo.ab. (3160)5. drug therapy.fs. (20)6. randomly.ab. (8231)7. trial.ab. (7527)8. groups.ab. (42,954)9. or/1-8 (56,348)10. (animals not (humans and animals)).sh. (8)11. 9 not 10 (56,346)12. Arthritis, Psoriatic/ (1)13. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (125)14. 12 or 13 (125)15. (etanercept or enbrel).ti,ab,rn. (164)16. (infliximab or remicade).ti,ab,rn. (287)17. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab,rn. (110)18. or/15-17 (438)19. 11 and 14 and 18 (5)  EMBASE: OvidSP    ■ http://ovidsp.ovid.com/󰀀e EMBASE search covered the date range 1980–2009 week 23 for adalimumab and 1 January 2004 to week 23 2009, using the search field ‘em: Entry Week’, for etanercept and infliximab. 󰀀e search was carried out on 9 June 2009 and identified 369 records.󰀀e strategy uses the Hedges Team best-sensitivity strategy for detecting clinically sound treatment studies in EMBASE (lines 17–20). 203 Note: A pragmatic approach was taken to reduce the number of irrelevant records retrieved and to negate the over indexing of records in EMBASE; EMTREE drug terms were focused in this strategy.1. Psoriatic Arthritis/ (4225)2. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (3339)3. 1 or 2 (5024)4. *Etanercept/ (1973)5. (etanercept or enbrel).ti,ab. (2192)6. *Infliximab/ (3482)7. (infliximab or remicade).ti,ab. (3991)8. or/4-7 (6134)9. (2004$or 2005$or 2006$or 2007$or 2008$or 2009$).em. (3,193,493)  © Queen’s Printer and Controller of HMSO 2011. All rights reserved. 137Health Technology Assessment 2011; Vol. 15: No. 10DOI: 10.3310/hta15100 10. 8 and 9 (4694)11. *Adalimumab/ (881)12. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab. (958)13. 11 or 12 (1236)14. 3 and 10 (500)15. 3 and 13 (219)16. 14 or 15 (561)17. random$.tw. (399,406)18. clinical trial$.mp. (608,378)19. exp Health Care Quality/ (802,714)20. or/17-19 (1,446,048)21. 16 and 20 (369) CENTRAL: The Cochrane Library    ■ www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOMEIssue 2, 2009, of 󰀀e Cochrane Library was searched to identify trials on CENTRAL. 󰀀e etanercept and infliximab search covered the date range 2004–2009. 󰀀e search for adalimumab had no date limits. 󰀀e search was carried out on 9 June 2009 and identified 37 records.#1 MeSH descriptor Arthritis, Psoriatic, this term only (99)#2 (psoria* NEAR/2 arthrit*) in Clinical Trials (132)#3 (psoria* NEAR/2 arthropath*) in Clinical Trials (6)#4 (#1 OR #2 OR #3) (199)#5 (etanercept or enbrel):ti,ab,kw, from 2004 to 2009 in Clinical Trials (184)#6 (infliximab or remicade):ti,ab,kw, from 2004 to 2009 in Clinical Trials (224)#7 (adalimumab or humira or D2E7 or (D2 adj E7)):ti,ab,kw in Clinical Trials (91)#8 (#5 OR #6 OR #7) (579)#9 (#4 AND #8) (37) SCI: ISI Web of Knowledge   ■ http://wok.mimas.ac.uk 󰀀e SCI search covered the date range 1990–2009 for adalimumab and 2004–9 for etanercept and infliximab. 󰀀e search was carried out on 9 June 2009 and identified 302 records.󰀀e strategy uses the terms used in the 2006 HTA report 73  to identify RCTs in the SCI (lines #1–7).# 13 302 #10 or #12Databases=SCI-EXPANDED Timespan=All Years# 12 108 #7 and #8 and #11Databases=SCI-EXPANDED Timespan=All Years# 11 1,676 TS=(adalimumab or humira or D2E7 or “D2 E7”)Databases=SCI-EXPANDED Timespan=All Years# 10 275 #7 and #8 and #9Databases=SCI-EXPANDED Timespan=2004–2009# 9 9,327 TS=(etanercept or enbrel or infliximab or remicade)Databases=SCI-EXPANDED Timespan=All Years# 8 4,706 TS=((psoria* same arthrit*) or (psoria* same arthropath*))Databases=SCI-EXPANDED Timespan=All Years# 7 >100,000 #5 not #6
Search
Similar documents
View more...
Tags
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks